Cargando…
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years
The first preparation of insulin extracted from a pancreas and made suitable for use in humans after purification was achieved 100 years ago in Toronto, an epoch-making achievement, which has ultimately provided a life-giving treatment for millions of people worldwide. The earliest animal-derived fo...
Autores principales: | Bolli, Geremia B., Cheng, Alice Y. Y., Owens, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296014/ https://www.ncbi.nlm.nih.gov/pubmed/35854185 http://dx.doi.org/10.1007/s00592-022-01938-4 |
Ejemplares similares
-
The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications
por: Owens, David R., et al.
Publicado: (2020) -
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021) -
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020) -
A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen
por: Bolli, Geremia B., et al.
Publicado: (2018) -
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%
por: Owens, David R., et al.
Publicado: (2019)